SELLAS Life Sciences Group Inc
RXK3
Company Profile
Business description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Contact
7 Times Square
Suite 2503
New YorkNY10036
USAT: +1 646 200-5278
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,178.90 | 53.70 | 0.66% |
| CAC 40 | 7,482.36 | 155.89 | 2.13% |
| DAX 40 | 21,961.97 | 668.44 | 3.14% |
| Dow JONES (US) | 39,606.57 | 419.59 | 1.07% |
| FTSE 100 | 8,403.18 | 74.58 | 0.90% |
| HKSE | 21,766.79 | 305.83 | -1.39% |
| NASDAQ | 16,708.05 | 407.63 | 2.50% |
| Nikkei 225 | 35,244.41 | 375.78 | 1.08% |
| NZX 50 Index | 12,037.81 | 81.34 | 0.68% |
| S&P 500 | 5,375.86 | 88.10 | 1.67% |
| S&P/ASX 200 | 7,972.10 | 51.60 | 0.65% |
| SSE Composite Index | 3,292.87 | 3.48 | -0.11% |